The development of small molecule antivirals that target viral RNA in Henipaviruses will benefit from a $1.7million grant from Open Philanthropy, a philanthropic funder prioritizing global health and wellbeing.
The pharma company provides funding to 24 community organizations throughout the US, as part of its newly created ‘Toward Health Equity Oncology Grant’.